Elucida Oncology Submits IND Application for ELU-001 for the Treatment of Cancers Overexpressing Folate-Receptor Alpha
19 juil. 2021 10h00 HE
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., July 19, 2021 (GLOBE NEWSWIRE) -- Elucida Oncology, a biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that it has submitted an...
Elucida Oncology Announces Three Key Additions to Its Board of Directors and the Appointment of Robert Essner as Chairman of the Board
29 avr. 2021 11h00 HE
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- Elucida Oncology, a biotechnology company pioneering the next frontier in targeted cancer therapy, announced today three key additions to...
Elucida Oncology to Present Preclinical Data on ELU001 at the American Association for Cancer Research Annual Meeting
29 mars 2021 10h15 HE
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Elucida Oncology, a biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that an abstract...
Elucida Oncology Closes $44 Million Series A-1 Financing
12 janv. 2021 09h15 HE
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Elucida Oncology, a biotechnology company pioneering the next frontier in targeted cancer therapy, announced today it has closed a $44...
Elucida Oncology to Present at the 39th Annual J.P. Morgan Healthcare Conference
07 janv. 2021 14h00 HE
|
Elucida Oncology, Inc
Elucida will also participate in the BIO Partnering @ JPM event MONMOUTH JUNCTION, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Elucida Oncology, a biotechnology company pioneering the next frontier in...
Elucida Oncology Appoints Dr. Eliel Bayever as Chief Medical Officer
01 oct. 2020 15h32 HE
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Elucida Oncology, a biotechnology company pioneering the next frontier in targeted cancer therapy, announced today the appointment of Dr....